Shares of Regeneron Pharmaceuticals REGN moved higher by 2.7% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 27.07% year over year to $9.53, which beat the estimate of $8.39.
Revenue of $2,423,000,000 up by 11.66% year over year, which beat the estimate of $2,420,000,000.
Guidance
Regeneron sees FY21 adjusted R&D of $2.7 billion-$2.85 billion.
Conference Call Details
Date: Feb 05, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/zhpbwhn8
Recent Stock Performance
Company's 52-week high was at $664.64
52-week low: $347.62
Price action over last quarter: down 11.39%
Company Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.